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Abstract
To overcome the intrinsic resistance of cancer cells to apoptotic stimuli, we
designed and synthesized approximately 50 novel β-carbolines structurally
related to harmine. Harmine is known for its anticancer properties and is a
DYRK1A inhibitor. Of the synthesized compounds, the most active in terms of
growth inhibition of five cancer cell lines are cytostatic and approximately 100
times more potent than harmine but demonstrated no DYRK1A inhibitory activity.
These novel β-carbolines display similar growth inhibitory activity in cancer cells
that are sensitive and resistant to apoptotic stimuli. Using ChemGPS-NP, we
found that the more active β-carbolines are all more lipophilic and larger than
the less active compounds. Lastly, on the basis of the NCI human tumor cell
line anticancer drug screen and the NCI COMPARE algorithm, it appears that
some of these compounds, including 5a and 5k, seem to act as protein synthesis
inhibitors. © 2012 American Chemical Society.
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ABSTRACT: To overcome the intrinsic resistance of cancer cells to apoptotic
stimuli, we designed and synthesized approximately 50 novel β-carbolines
structurally related to harmine. Harmine is known for its anticancer properties
and is a DYRK1A inhibitor. Of the synthesized compounds, the most active in
terms of growth inhibition of ﬁve cancer cell lines are cytostatic and
approximately 100 times more potent than harmine but demonstrated no
DYRK1A inhibitory activity. These novel β-carbolines display similar growth
inhibitory activity in cancer cells that are sensitive and resistant to apoptotic
stimuli. Using ChemGPS-NP, we found that the more active β-carbolines are all
more lipophilic and larger than the less active compounds. Lastly, on the basis of
the NCI human tumor cell line anticancer drug screen and the NCI COMPARE
algorithm, it appears that some of these compounds, including 5a and 5k, seem to
act as protein synthesis inhibitors.
■ INTRODUCTION
Cancer is becoming an increasingly important cause of death,
and more than 80% of all anticancer drugs target the apoptosis
pathways of tumor cells.1a−c However, as emphasized by
Wong,1c cancer is a disease in which too little apoptosis occurs,
resulting in malignant cells that will not die. In addition, the
mechanisms underlying apoptosis are complex and involve
multiple pathways in which many defects can occur in cancer
cells (e.g., p53 mutations that occur in approximately 50% of
cancers2), leading to resistance to anticancer drugs.1c However,
drug resistance is also seen in cancers expressing wild-type
p53.1c In fact, in addition to defects in the normal regulation of
apoptotic pathways, cancer cells also develop resistance to
cytotoxic molecules via the activation of membrane transporters
that actively pump drugs out of the cells (the so-called
“multidrug resistance” (MDR) phenotype), changes in the
glutathione system and altered metabolism.3a,b Finally, several
cancer types are also able to develop resistance to receptor
tyrosine kinase inhibitors (RTKIs), to RTK-targeting antibod-
ies, and to antibodies that inactivate ligands for RTKs.3a Brain
cancers (e.g., glioblastoma,),4a esophageal cancers,4b,c melano-
mas,4d pancreatic cancers,4e and non-small-cell lung cancers
(NSCLCs)4f are among the cancers associated with the worst
prognoses because of their ability to resist most if not all of the
current chemotherapies. It should therefore be emphasized that
we have made use of glioblastoma and esophageal cancer
models to characterize the in vitro anticancer eﬀects of the
compounds developed in this study.
We designed a novel strategy to try to overcome, at least
partly, the intrinsic resistance of cancer cells to apoptotic
stimuli. We synthesized novel molecules that are structurally
related to harmine, which is a naturally occurring β-carboline
that was previously isolated from plants, including the Middle
Eastern grass harmal or Syrian rue (Peganum harmala) and the
South American vine ayahuasca (Banisteriopsis caapi).5a,b We
chose harmine as a scaﬀold to generate novel derivatives
because (i) harmine is associated with anticancer activity,6 (ii)
harmine has been repeatedly shown to inhibit the protein
kinase DYRK1A (dual speciﬁcity tyrosine-phosphorylated and
regulated kinase 1a),7a−c (iii) overexpression of DYRK1A has
been implicated in multiple diseases, tumorigenesis, and
uncontrolled cell proliferation,8 (iv) harmine-mediated inhib-
ition of DYRK1A induces the activation of caspase-9, which
leads to massive apoptosis in diﬀerent human cell types,7c and
(v) melanomas that are intrinsically resistant to apoptotic
stimuli overexpress DYRK1A.9 In addition, it has been recently
shown that harmine can reverse resistance to anticancer drugs
by inhibiting the breast cancer resistance protein BCRP.10
Received: April 17, 2012
Published: July 9, 2012
Article
pubs.acs.org/jmc
© 2012 American Chemical Society 6489 dx.doi.org/10.1021/jm300542e | J. Med. Chem. 2012, 55, 6489−6501
Table 1. Determination of the in Vitro IC50 Growth Inhibitory Activity Associated with Each Compound That Has Been
Cultured for 3 Days in the Presence (or the Absence, Control) of the Various Cancer Cell Linesa
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Recently, our group reported the inhibitory activity of a
series of 7-substituted harmine derivatives against monoamine
oxidase A (MAO-A).11 In the present work, we examined a
larger series of compounds and investigated the in vitro growth
Table 1. continued
aThe dash indicates not determined.
Scheme 1. Synthesis of β-Carbolines 3a−n, 4a−g, and 5a−zaa
a(a) HBr, HAc, reﬂux, overnight ; (b) Cs2CO3, R1X, DMF, rt or Δ ; (c) 3g, NaH, iodopropane, DMF, 24 h; (d) KOH (5 equiv), DMF, rt, 30 min,
then R1(=R2)-Br, rt, 24 h (procedure A); (e) R3-Br (10 equiv), THF, Δ, 48 h (procedure B), or microwave, 155 °C, 4 h (procedure C); (f) 4a, Pd/C
(10%), MeOH, rt, 48 h.
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inhibitory eﬀects of these compounds using both the
colorimetric MTT assay12a−d and computer-assisted phase-
contrast microscopy (i.e., quantitative videomicroscopy).13a−d
Three glioma and two esophageal cancer lines were used for the
MTT assays, including the U373 glioma12c,14 and the OE21
esophageal4c cancer cell lines that display signiﬁcant levels of
resistance to apoptotic stimuli. Harmine was used as a reference
compound. The U373 glioma cell line was used for the
quantitative videomicroscopy analyses. Several compounds
were also biochemically assayed for their anti-DYRK1A activity.
Several of the most potent compounds in terms of in vitro
growth inhibitory activity were then evaluated in a 60-cancer-
cell-line panel at the NCI (Developmental Therapeutic
Program, Division of Cancer Treatment and Diagnosis) in
order to compare their mechanism(s) of action to those of the
over 763 000 compounds already available in the NCI
database.15 Finally, we used a “ChemGPS-NP” approach,16a−c
which is a global physicochemical space model, in order to
investigate the region of chemical space where the examined
series of compounds are localized.
■ RESULTS
Chemistry. The monosubstituted derivatives 3a−m (Table
1) were synthesized following a two-step procedure involving
the demethylation of harmine (1) to the corresponding harmol
(2), followed by realkylation to generate the corresponding 7-
substituted β-carboline derivative 3a−m (Scheme 1). The key
intermediate 2 was generated via cleavage of the methyl ether
present in harmine 1 with hydrobromic acid. The 7-substituted
β-carbolines 3a−m were obtained via O-alkylation of 2 in the
presence of cesium carbonate with the corresponding alkyl
halide. The 7,9-disubstituted compounds 4a−f were obtained
via simultaneous O7- and N9-alkylation of 2 using 2 equiv of
alkyl halide and 5 equiv of potassium hydroxide in DMF.
Compound 4a was obtained via reduction using Pd/C. The
2,7,9-trisubstituted β-carbolin-2-ium bromides 5a−za were
obtained from the corresponding 7,9-disubstituted compound
4 following N2-alkylation in THF using 10 equiv of the
corresponding alkyl bromide. The structure and the purity of
each ﬁnal compound were characterized via 1H NMR, 13C
NMR, mass spectrometry (MS), elemental analyses, and
HPLC.
Pharmacological Evaluation. Determination of the in
Vitro Growth Inhibitory Activity. The growth inhibitory
potency of the approximately 50 synthesized compounds was
evaluated in three glioma cell lines (U373, T98G and Hs68317)
and two esophageal cancer cell lines (OE21 and OE334c) using
the MTT assay. The cells were cultured for 3 days in the
absence (control) or presence of the synthesized compound-
s.12a−d Most of the 2,7,9-trisubstituted compounds 5a−za
(except 5e, 5h, 5r, and 5t; Table 1) exhibited mean IC50 values
at least 10 times lower than that of harmine (1) (Table 1).
Among the 7-monosubstituted β-carbolines 3a−m, the
replacement of the 7-CH3O of harmine with various alkoxy
groups 3a−e generated molecules with a mean IC50 ranging
from 22 to >100 μM; the IC50 of harmine was 28 μM (Table
1). By contrast, the replacement of the methyl group of
harmine (1) by a cyclohexylmethyl 3f, a benzyl 3g, a phenethyl
3h, a 2′- and 4′-pyridyl-CH2 3j,l, or a naphthyl-CH2 slightly
augmented the growth inhibitory potency of these compounds
when compared to 1 (the mean IC50 ranged from 5 to 20 μM,
Table 1).
The addition of a substituent in position 9 decreased the
mean growth inhibitory potency when compared with the
corresponding 7-monosubstituted β-carbolines (the following
pairs of compounds should be compared: 3b/4e, 3f/4d, 3g/4a,
and 3g/4f; Table 1). By contrast, the introduction of a second
substituent on position 2 increased the in vitro growth
inhibitory activity, as demonstrated by the 2,7-dibenzyl-β-
carboline 4g (IC50 = 5 μM) when compared with the 7,9-
dibenzyl derivative 4a (IC50 = 31 μM) or harmine (1, 28 μM).
Finally, we synthesized β-carbolines bearing substituents in
the 2, 7, and 9 positions, 5a−za. Interestingly, apart from 5h
that was as potent as 1, all of these trisubstituted molecules
were more potent in inhibiting cancer cell line growth than the
parent compound with a mean IC50 ranging from 0.3 to 5 μM
(Table 1). Compounds 5a, 5b, 5g, 5l, 5o, 5p, 5s, and 5v
displayed a mean IC50 in the submicromolar range (Table 1).
As shown in Table 1, the synthesized compounds display in
vitro growth inhibitory eﬀects that are similar in cancer cell
lines and are sensitive to apoptotic stimuli (Hs68312c,14 and
OE334c) or resistant to apoptotic stimuli (U37312c,14 and
OE214c). While this ﬁnding strongly suggests that the growth
inhibitory activity of the compounds is not due to the cytotoxic
eﬀects of the compounds or to the induction of apoptosis,
quantitative videomicroscopy was used to evaluate the
cytostatic and/or cytotoxic activity of selected β-carbolines in
the human U373 glioma cell line as detailed below.
Table 2. Pharmacological Analyses of Compounds 1, 3c, 3k, 4a, 4d, 5a, 5k, and 5o
compd
DYRK1A
inhibition,
IC50 (μM)
mean in vitro growth inhibition concns
determined by MTT colorimetric assay in
ﬁve human cancer cell line (see Table 1),
IC50 (μM)
global growth ratio (GGR index) (μM) determined
by quantitative videomicroscopy in the U373 glioma
cell line at the MTT colorimetric assay related IC50
concn
global proﬁle of the
compound in terms
of growth
inhibition
solubility in
PBS, pH
7.4, at rt
(μM)
1
(harmine)
0.08a 28 ± 3 0.30 at 32 cytostatic ND
3c 16 60 ± 3 0.23 at 64 cytostatic ND
3k 10 29 ± 1 0.29 at 24 cytostatic ND
4a 16 31 ± 4 0.30 at 18 cytostatic <3
4d >10 25 ± 4 0.17 at 31 cytostatic ND
5a 21 0.7 ± 0.2 0.40 at 0.4 cytostatic 461
5k b 2.7 + 0.6 0.53 at 0.9 cytostatic 53
5o 43 0.34 ± 0.05 0.25 at 0.4 cytostatic 123
aTaken from ref 7a. The DYRK1A IC50 concentration relating to each compound was determined by using 10 concentrations ranging from 10
−4 to 3
× 10−8 M, in triplicate. Compound 4d was tested in the range 5 × 10−5 M to 1.5 × 10−9 M, in triplicate. A radiometric protein kinase assay
(33PanQinaseR activity assay) was used for measuring the kinase activity of DYRK1A protein kinase as detailed in the Experimental Section. bNot
determined
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Interestingly, the 2,7,9-trisubstituted β-carbolin-2-ium bro-
mides 5 were also characterized by higher aqueous solubility
compared to the disubstituted compounds (Table 2, compare
5a, 5k, 5o vs 4a). This can certainly be attributed to the
presence of a permanent positive charge on the trisubstituted
compounds.
Evaluation of DYRK1a Kinase Inhibition. As harmine (1)
has been reported to be a DYRK1A inhibitor, a panel of mono-
(3c,k), di- (4a, 4d), and tri- (5a, 5o) substituted β-carbolines
was selected, and their DYRK1A inhibitory potency was
evaluated using a radiometric protein kinase assay (33PanQinase
Activity Assay). These compounds were also analyzed via
quantitative videomicroscopy as detailed in the next section.
The IC50 values for the harmine derivatives were calculated
using dose−response curves. These IC50 values ranged from 10
to 43 μM; therefore, these compounds were much less active
than harmine (IC50 = 0.08 μM; Table 2). Surprisingly, the two
most active compounds (5a, 5o) in terms of growth inhibitory
activity in U373 glioma cells (Table 1) were the worst
inhibitors of DYRK1A (IC50 of 21 and 43 μM, respectively).
Cytotoxic and Cytostatic Eﬀects of Various Compounds in
U373 Glioma Cells. U373 glioma cells were seeded and
cultured (T25 cm2 ﬂasks) for 72 h in the absence (control) or
the presence of various β-carbolines at their growth inhibitory
IC50 (Table 2). The compounds analyzed using quantitative
videomicroscopy were those assayed for anti-DYRK1A activity.
The quantitative videomicroscopy approach enabled an image
of the bottom of the seeded ﬂask to be taken every 4 min over
the course of a 72 h observation period.13a−d Thus, 1080
digitized images were available for each experimental condition,
which were run in triplicate, and an approximately 40 s movie
was generated from these images. These movies clearly
demonstrate that the analyzed compounds displayed cytostatic,
not cytotoxic, eﬀects in the U373 glioma cells. A morphological
illustration of the cytostatic eﬀects induced by 1 and 5a is
provided in Figure 1. For each compound analyzed (Table 2), a
global growth ratio (the GGR index) was further calculated,
resulting in a value that can be directly compared to the MTT-
assay-determined IC50 value. First, the global growth (GG) is
calculated in each control and in each treated condition by
dividing the number of cells on the last image by the number of
cells on the ﬁrst image. The GGR index is obtained for each
compound by dividing the GG values calculated for treated
U373 cells by the GG values calculated for the control. As
shown in Table 2, the compounds appeared more inhibitory
based on their IC50 values calculated using the MTT assay
when compared with the quantitative videomicroscopy results
because the GGR indices were always less than 0.5. This could
be because U373 cells grow faster in T25 cm2 ﬂasks (a ﬁnal
volume of 7 mL) than in 96-well plates (a ﬁnal volume of 100
μL). However, even if the IC50 values calculated based on the
MTT assay resulted in GGR indices less than 0.5, these
compounds displayed cytostatic, not cytotoxic, eﬀects (Figure
1, Table 2).
As the most active compounds 5a, 5k, 5o under study in
terms of in vitro growth inhibitory activity in U373 glioma cells
(Table 1) were the worst inhibitors of DYRK1A (Table 2)
while these compounds displayed cytostatic, not cytotoxic,
eﬀects (Table 2), we submitted 5k to a kinase proﬁling
including 358 kinases and 10 lipid kinases (Table 3). At 10 μM,
5k decreased by >90% the activity of a dozen of kinases (Table
3) that are implicated in cell proliferation in general and more
particularly in tumor cell proliferation, such as CAMK,18a,b
MYLK,18c TGF-β receptors,18d,e FER,18f TEC,18g and CSK,18h a
feature that can explain at least partly the 5k-induced cytostatic
eﬀects in cancer cells (Table 2). We choose 5k instead of 5a or
Figure 1. Quantitative videomicroscopy analyses of the in vitro anticancer activity of harmine (1) and 5a in the human U373 glioblastoma cell line.
Compounds 1 and 5a were assayed at their respective in vitro growth inhibitory IC50 value, as determined using the MTT assay in U373 glioma cells
(see Table 1).
Table 3. Proﬁling of 5k at 10 μM against 358 Protein
Kinases and 10 Lipid Kinasesa
kinase name
kinase
family
mean residual activity (%) (duplicate
measurements)
STK17A CAMK <1
CAMK2A 1
CAMK2D 2
MYLK 2
MYLK2 7
MKNK1 10
TGFB-R1 TKL 6
TGFB-R2 6
FER TK 7
TEC 8
CSK 10
aOnly kinases inhibited at >90% are shown.
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5o for the kinase proﬁling because 5k appeared less toxic in
vivo (analyses of the maximal tolerated dose in healthy mice)
than 5a or 5o (data not shown).
Rationalization of the SAR Analyses. On the basis of these
results, we have generated a series of compounds displaying in
vitro cytostatic growth inhibitory activity against human cancer
cell lines displaying various levels of resistance to apoptotic
stimuli at the submicromolar range. Unexpectedly, we also
found that these compounds, in fact, did not act as DYRK1A
inhibitors. Moreover, structure−activity relationships (SARs)
were not easy to infer, as aromatic, substituted or not, and alkyl
substituents resulted in molecules with a wide range of activities
(mean IC50 from 0.34 to 5 μM). Therefore, to provide a
possible explanation for the observed trend in the SAR analyses
we reported above, we undertook an analysis using ChemGPS-
NP.16a−c
ChemGPS-NP is a global model of chemical property space
based on principal component analysis (PCA) that provides a
positioning system tuned for the exploration of biologically
relevant chemical space (i.e., those areas of chemical space most
likely to enclose biologically active compounds). This is
achieved by positioning the chemical compound properties
using PCA score prediction onto a consistent eight-dimensional
(8D) map based on structure-derived physicochemical
characteristics for a reference set of compounds.16a−c As with
any PCA, the largest variability in data occurs in the ﬁrst
principal component (PC1), with successfully decreasing
information content in the following PCs. The ﬁrst four
dimensions of the ChemGPS-NP map, accounting for 77% of
data variance, can be interpreted in such a way that PC1
primarily represents size, shape, and polarizability; PC2
corresponds to aromatic- and conjugation-related properties;
PC3 describes lipophilicity, polarity, and H-bond capacity; and
PC4 expresses ﬂexibility and rigidity.16a−c For a more detailed
explanation of ChemGPS-NP chemical property loadings, refer
to the work by Rosen et al.16c Any compound, real or virtual,
with a known chemical structure can be positioned in
ChemGPS-NP property space. From the resulting projections,
properties of the compounds, together with trends and clusters
of very large data sets, can be compared and easily interpreted.
From this analysis (Figure 2), we can see that all of the tested
β-carbolines are comparably closely positioned in the chemical
space; they are not particularly large (PC1 contribution), quite
aromatic (PC2 contribution), and lipophilic (PC3 contribu-
tion). Interestingly, all the compounds with the greatest in vitro
growth inhibitory activity (Tables 1 and 2), represented as red
dots in Figure 2, are well separated from the less active
compounds, represented as blue dots. The more active
compounds are all more lipophilic and larger than the less
active compounds, and the degree of aromaticity varies within
approximately the same range. If we compare this series of β-
carbolines with a set of approximately 20 000 compounds from
the ZINC-NP (http://zinc.docking.org) database (Figure 2B),
which can be seen as a simple generalization of “druglike
natural products”, one can see that the derivatives examined in
this study are distinct from the majority of the compounds
found in the ZINC-NP database. The internal structure visible
in the ZINC-NP cloud is mainly due to diﬀerent degrees of
aromaticity.
Analyses of the in Vitro Growth Inhibitory Activity
Associated with 5a, 5k, and 5o in the NCI 60-Cancer-Cell-
Line Panel. Compounds 5a, 5k, and 5o were ﬁrst analyzed by
the NCI in their 60-cell-line panel at 10 μM. As shown in
Figure 3, revealed with the permission of the NCI, treatment
with 10 μM 5a resulted in 45% in vitro growth inhibition if the
60 cell lines are taken as a whole (Figure 3A). However, the
diﬀerence in the magnitude of growth inhibition between the
less and more sensitive cancer cell lines at this concentration
was over 2 logs (Figure 3A). Quite similar data were obtained
for 5k (data not shown). By contrast, the in vitro growth
inhibition proﬁle of 10 μM 5o (Figure 3B) diﬀered from the
proﬁles of both 5a (Figure 3A) and 5k (data not shown). As
shown in Figure 3B, treatment with 10 μM 5o resulted in
approximately 80% in vitro growth inhibition if the 60 cell lines
are taken as whole, and the magnitude of the diﬀerence in
growth inhibition between the less and the more sensitive
cancer cell lines was smaller. These data suggest that 5a and 5k
could share relatively common mechanism(s) of action, at least
in vitro, whereas the mechanism of action of 5o likely diﬀers
from those of 5a and 5k, even if the three compounds were
clearly identiﬁed as cytostatic compounds (Figure 1, Table 2).
We then calculated the “COMPARE correlation coeﬃcients”
for 5a, 5k and 5o using the COMPARE software developed by
the NCI (Table 4). The highest correlation coeﬃcient for 5a
reached 0.83−0.85 for four compounds whose chemical
structures are illustrated in Table 4. The highest coeﬃcient
correlation found for 5k was 0.82 and corresponded to 5a. The
highest correlation coeﬃcient for 5o reached 0.73−0.78 for
four compounds whose chemical structures are also illustrated
in Table 4. In the discussion section, we detail the previously
described mechanisms underlying the anticancer activity of
these compounds, e.g., protein synthesis inhibition. We
therefore wanted to validate at the biochemical level the
theoretical analyses we performed using the COMPARE
approach (Table 4). We thus analyzed by means of Western
blotting the eﬀects of 5a and 5k (which behave as protein
synthesis inhibitors according to the data illustrated in Table 4)
and 5o (which does not behave as a protein synthesis inhibitor
according to the data illustrated in Table 4) on the eukaryotic
initiation factor 2 (eIF2) in Hs683 oligodendroglioma and
U373 glioblastoma cells (Figure 4). The data obtained show
that 5a and 5k decreased both eIF2 activity (at its
phosphorylation levels) and expression in Hs683 and U373
glioma cells after a treatment of 4 h at their respective IC50
Figure 2. (A) ChemGPS-NP mapping of compounds investigated in
the present study. Blue dots indicate the compounds with less in vitro
growth inhibitory activity in ﬁve human cancer cell lines, and red dots
indicate the compounds with more inhibitory activity (see Table 1).
(B) ChemGPS-NP mapping of compounds investigated in this study
combined with a small reference set of approximately 20 000
compounds from the ZINC-NP database (http://zinc.docking.org),
which can be considered a simple generalization of “natural products”.
The red box indicates PC1 (size, weight, etc.). The yellow box
indicates PC2 (aromaticity, rigidity, etc.), and the green box indicates
PC3 (lipophilicity, etc.).
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growth inhibitory concentrations (Table 1), while these eﬀects
appeared less pronounced, if any, with 5o using the same
experimental conditions (Figure 4).
■ DISCUSSION AND CONCLUSIONS
In an attempt to develop compounds to overcome the intrinsic
resistance of cancer cells to apoptotic stimuli, we designed and
synthesized novel β-carbolines that are structurally related to
harmine. Harmine is known for its anticancer properties and is
a DYRK1A inhibitor, an enzyme involved in uncontrolled cell
proliferation7c,8 and cancer cell chemoresistance10 that is
overexpressed in melanomas intrinsically resistant to apoptotic
stimuli.9
The data we obtained in the current study indicate that we
generated cytostatic compounds, with the more potent
compounds approximately 2 orders of magnitude more active
than harmine in inhibiting cancer cell proliferation. Impor-
tantly, these compounds inhibit the growth of apoptosis-
resistant cancer cells, with growth inhibitory activity in the
submicromolar range, but are weak DYRK1A inhibitors.
Proﬁling the anti-kinase activity of 5k revealed that 5k-induced
cytostatic eﬀects (Table 2) relate to inhibition of the activity of
kinases involved in tumor cell proliferation including a dozen of
CAMK, TKL, and TK kinases (Table 3). A 72 h stability study
in cell culture medium without serum was performed with 5a or
5o, and we recovered greater than 95% of these two
compounds (data not shown), suggesting that the cytostatic
eﬀects displayed by 5a and 5o are not the result of degradation
products.
The β-carbolines we synthesized seem to be located in a
distinct chemical space when compared with approximately 20
000 previously analyzed compounds. While the ChemGPS-NP
visualization provided initial insights in the physicochemical
diﬀerences between the more and less active compounds
(Figure 2), its full predictive power has not yet been harnessed.
This subsequent step would require interpreting the observed
physicochemical diﬀerences and designing a novel set of
harmine derivatives. One interpretational tool that could be
used for this purpose is an orthogonal partial least squares
discriminant analysis (OPLS-DA), which deﬁnes diﬀerences in
properties between two groups (e.g., more and less active or
active and nonactive compounds). The result from an OPLS-
DA provides a plot of all 35 descriptors and describes their
relative contribution to the diﬀerences between the analyzed
subsets. With this information, a rational approach to further
derivatization can be undertaken. In addition to this analysis,
further insights can be gained by continuously predicting
derivatives in the ChemGPS-NP chemical property space. This
can easily be performed before the actual chemical reactions are
performed if an educated guess regarding the structure of the
novel product can be made. The SMILES string of the
anticipated structure can then be obtained, and the position
predicted and evaluated, with regard to the already identiﬁed
top hits. At present, as shown in Figure 2, all of the most active
compounds are signiﬁcantly more lipophilic (larger values along
Figure 3. Characterization of the eﬀects induced by 10 μM 5a (A) and 10 μM 5o (B) in the NCI 60-cell-line panel.
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PC3) than the less active compounds. Other properties also
associated with PC3 apart from lipophilicity are polarity, H-
bond capacity, mean electronegativity, and topological polar
surface area with regard to N, O, S, and P, with all the latter
negatively correlated in a signiﬁcant way. An initial step to
further explore and maybe optimize the harmine derivatives
would be to probe if an even larger value along PC3 would
result in compounds with even more activity and designing new
derivatives with the above aspects.When compared with the
small ZINC-NP reference set in Figure 2B, the tested harmine
derivatives already display properties that place them on the
border of the reference compound cloud. With a larger and
more comprehensive set of natural products this is, however, no
longer the case, and property-wise, we therefore still move in
charted territories.
We requested the help of the Developmental Therapeutic
Program (Division of Cancer Treatment and Diagnosis,
National Cancer Institute, Rockville, MD, U.S.)15 to investigate
whether the in vitro growth inhibitory activities of β-carbolines
5a, 5k, and 5o match or do not match those of the more than
763 000 compounds already available in the NCI database.
Indeed, the NCI has evaluated the in vitro growth inhibitory
proﬁles of a large number of synthetic compounds, natural
products, and plant extracts on 60 diﬀerent cell lines.15 The
growth inhibitory proﬁle of novel compounds (such as the
harmine derivatives examined in the current study) on each of
the 60 cell lines is stored in a database that can be analyzed by
the COMPARE algorithm, as this program ranks all entries for
similarity of growth inhibitory proﬁles between investigational
and reference compounds.19 The degree of similarity between
the growth inhibitory proﬁles is expressed numerically as a
Pearson correlation coeﬃcient (Table 4).19 As emphasized by
Chan et al.,20 the COMPARE algorithm has already been
successfully used to identify novel inhibitors of tubulin
polymerization,21a inosine monophosphate dehydrogenase,21b
topoisomerase I,21c and cyclin-dependent kinases.21d Chan et
al.20 used the same approach to search for novel inhibitors of
protein synthesis, and they identiﬁed 31 known protein
synthesis inhibitors, including phyllantoside and nagilactone
C. Using this approach, we found that the four highest Pearson
correlation coeﬃcients found for 5a and 5k related to protein
synthesis inhibitors, including NSC634791, NSC267709
(undulatone), and NSC342443 (phyllantoside) (Table 4),
which are among the 31 protein synthesis inhibitors identiﬁed
Table 4. Correlations of the Diﬀerential Cellular Sensitivities in the NCI 60-Cell-Line Screen Using the COMPARE Algorithma
a“COMPARE correlation coeﬃcients” were generated by a computerized pattern recognition algorithm and serve as an indication of similarities in
diﬀerential cellular sensitivities of characteristic ﬁngerprints for each compound. The COMPARE coeﬃcient of correlation reported in this table
relies on the comparison of the growth inhibitory concentration by 50% (GI50) between “xx” cell lines (indicated in parentheses in Table 4) for
either compound 5a or 5o versus the >763000 compounds already available in this data base. The four highest correlations found for either 5a or 5o
among the ≳763000 analyzed compounds are reported in this table. Additional information about the DTP human tumor cell line screen is available
at http://dtp.nci.nih.gov/branches/btb/ivclsp.html.
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by Chan et al.20 Phyllantoside was ﬁrst isolated from an
ethanolic extract prepared from the Central American tree
Phyllantus acuminatus based on bioassay-guided cytotoxicity
fractionation.22 We did not ﬁnd any description of the
mechanism of action of the fourth compound with a growth
inhibitory proﬁle similar to 5a and 5k, NSC644614 (Table 4).
One of the four compounds with the highest correlation in
terms of growth inhibitory proﬁles when compared with 5o was
NSC747162 (mitotempol), a superoxide dismutase mimetic
that interferes with statin activity.23 Therefore, 5o does not
seem to act as a protein synthesis inhibitor, in contrast to 5a
and 5k. Western bloting analyses revealed that 5a and 5k, but
not 5o, decreased both activity and expression of the eukaryotic
initiation factor 2 (eIF2) in Hs683 and U373 glioma cells
(Figure 4).
As emphasized by Chan et al.,20 numerous studies have
already indicated that deregulation of protein synthesis is a
major contributor to cancer initiation and metastatic pro-
gression. The overexpression of some initiation factors can lead
to malignant transformation, whereas down-regulation of these
same factors can suppress the transformed phenotypes.
Components of the translation machinery are frequently
overexpressed or mutated in cancer cells, and key components
of antiapoptotic pathways are also translationally regulated.20 A
therapeutic index can be obtained with protein synthesis
inhibitors because the transformed cells require higher levels of
protein synthesis and because of the translational regulation of
some of the proteins involved in cancer progression.20 Again, as
emphasized by Chan et al.,20 little eﬀort has been made to
systematically search for new inhibitors of eukaryotic protein
synthesis, with most of the compounds that are currently used
having been identiﬁed in chemical screens performed several
decades ago.
In conclusion, having generated approximately 50 novel
derivatives of harmine, a potent DYRK1A kinase inhibitor, we
obtained several compounds that displayed signiﬁcantly higher
growth inhibitory activity than harmine while having lost anti-
DYRK1A activity but keeping anti-kinase activity with respect
to a dozen of CAMK, TLK, and TK kinases. The most active
compounds from the current study display similar growth
inhibitory activity in both cancer cells that are sensitive to
apoptotic stimuli and cancer cells that are resistant apoptotic
stimuli. Compared with the more than 763 000 compounds
already present in the NCI database using the NCI COMPARE
analysis, some of these compounds, including 5a and 5k, appear
to act as protein synthesis inhibitors, a feature that has been
biochemically validated with 5a and 5k that we showed to
inhibit the activity of the eukaryotic initiation factor 2 (eIF2).
We are now developing a biochemical assay to determine the
mechanism of protein synthesis inhibition associated with each
compound we generated in order to derive novel protein
synthesis inhibitors with signiﬁcant therapeutic indices between
normal and cancer cells.
■ EXPERIMENTAL SECTION
Chemistry. Melting points were measured by DSC with a Perkin-
Elmer DSC 7.0 Pro apparatus and recorded with Pyris software. NMR
spectra were recorded on a Jeol spectrometer (JNM ECX 400). The
1H NMR, 13C NMR, and 19F NMR spectra were recorded at 400, 100,
and 376 MHz, respectively. The chemical shifts are reported in parts
per million (ppm) relative to the singlet at 7.26 ppm for chloroform in
CDCl3, the singlet at 2.50 ppm from dimethyl sulfoxide in (CD3)2SO,
and the singlet at 3.31 ppm for methanol in CD3OD, and the coupling
constants are in Hz. The following abbreviations are used for spin
multiplicity: s, singlet; d, doublet; t, triplet; q, quadruplet, qt,
quintuplet; m, multiplet; b, broad. Routine thin-layer chromatography
(TLC) was performed on silica gel plates (silica gel GF254, VWR).
Column chromatography was performed on a BiotageSP1 25+M
column (ﬂow of 25 mL/min; spherical particle size 60−200 μm; MP
Biomedicals) equipped with a UV spectrophotometer as a detector
(wavelengths of 254 and 320 nm). Solvents from Aldrich and VWR
were used without further puriﬁcation. The purity of the compounds
was evaluated via either microanalysis or LC−MS. This information is
available in the Supporting Information. Analytical LC−MS analyses
were performed on an Agilent 1100 series HPLC coupled with an
MSD Trap SL system using UV detection at 220 and 254 nm. Mass
spectra were recorded using electron spray ionization (ESI) operating
in positive mode. The following methods were used: method A,
injection of 10 μL of a 20 μg·mL−1 solution onto a Agilent Zorbax
Eclipse XDB C8 4.6 mm × 150 mm, 5 μm separation column using a
70:30 solution of 0.01 M butane sulfonate in water/0.01 M butane
sulfonate in methanol as the eluent; method B, injection of 5 μL of a
50 μM CH3CN solution onto an Kinetex Hilic 100 mm × 2.1 mm, 2.6
μm separation column using a gradient of 100% B to 60% B within 8
min, then reversing to 100% B in 5 min (solution A, 25 mL of a 4%
HAc/0.4% triﬂuoroacetic acid solution diluted in 500 mL water;
solution B, 25 mL of a 4% HAc/0.4% triﬂuoroacetic acid diluted in
500 mL of acetonitrile). All new compounds were determined to be
>95% pure by microanalysis or LC−MS.
General Synthetic Procedure A for Simultaneous O7- and
N9-Alkylation of 1-Methyl-7-hydroxy-β-carboline. The 1-methyl-
7-hydroxy-β-carboline 2 (500 mg, 1.587 mmol) was dissolved in N,N-
dimethylformamide (20 mL), and an amount of 5 equiv of potassium
hydroxide was added. The mixture was stirred for 30 min under argon.
Then an amount of 2 equiv of the alkyl bromide was added, and the
mixture was stirred at room temperature for 24 h under argon. The
reaction was followed by TLC (85:15 CH2Cl2/ethanol). At the end of
the reaction, the reaction mixture was extracted using dichloromethane
(30 mL). The organic layer was washed twice with brine (2 × 30 mL)
and dried with MgSO4, which was collected by ﬁltration. The organic
layer was ﬁnally evaporated under vacuum to produce the crude
product, which was puriﬁed via column chromatography as described
in the general section with a mobile phase of cyclohexane/ethyl acetate
(from 80:20 to 50:50) used as the eluent.
General Synthetic Procedure B for N2-Alkylation of 1-
Methyl-O7-substituted-N9-substituted-7-hydroxy-β-carboline.
The 1-methyl-O7-substituted-N9-substituted-7-hydroxy-β-carboline
Figure 4. Western blotting analyses of the eﬀects of 5a, 5k, and 5o on
the activity (phosphorylation levels) and expression of the eukaryotic
initiation factor 2 (eIF2). Each compound was assayed at its IC50
growth inhibitory concentration in Hs683 and U373 glioma cells as
determined by means of the MTT colorimetric assay (Table 1), i.e.,
0.5 μM 5a, 5 μM 5k, and 0.5 μM 5o in Hs683 cancer cells and 0.5 μM
5a, 1 μM 5k, and 0.5 μM 5o in U373 ones.
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(100 mg) was dissolved in THF (15 mL). An amount of 10 equiv of
alkyl bromide was added, and the mixture was reﬂuxed for 48 h under
argon. The reaction was followed by TLC (85:15 CH2Cl2/ethanol). At
the end of the reaction, the solvents were evaporated under vacuum to
produce the crude product, which was further puriﬁed via column
chromatography as described in the general section with a mobile
phase of 95:5 dichloromethane/ethanol used as the eluent.
General Microwave-Assisted Synthetic Procedure C for the
N2-Alkylation of 1-Methyl-O7-substituted-N9-substituted-7-hy-
droxy-β-carboline. The 1-methyl-O7-substituted-N9-substituted-7-
hydroxy-β-carboline (200 mg) was dissolved in THF (10 mL). An
amount of 10 equiv of alkyl halide was added, and the mixture was
placed in a microwave reactor at 155 °C for 4 h. At the end of the
process, TLC (85:15 CH2Cl2/ethanol) was performed. The solvents
were then evaporated under vacuum to produce the crude product,
which was puriﬁed via column chromatography as described in the
general section with a mobile phase of dichloromethane/ethanol (from
100:0 to 85:15) used as the eluent.
Syntheses. The synthesis of compounds 2 and 3a−m has been
previously reported.11 A full description of the synthesis of compounds
3n and 5a−za can be found in the Supporting Information.
1-Methyl-7-benzyloxy-9-benzyl-β-carboline (4a). The title
compound was synthesized according to the general synthetic
procedure A from 1-methyl-7-hydroxy-β-carboline 2 (1.0 g, 3.173
mmol) in the presence of 1-bromomethylbenzene (1.085 g, 6.346
mmol). White powder, yield 66%; Rf = 0.88 (CH2Cl2/ethanol 85/15);
mp 156 °C; m/z [MH+] 379.2. 1H NMR (400 MHz, DMSO-d6) δ
(ppm): 2.70 (s, 3H, CH3), 5.14 (s, 2H, O-CH2), 5.84 (s, 2H, N-CH2),
6.88 (d, 2H, 2ArH), 6.94 (dd, J6−5 = 8.7 Hz, J6−8 = 2.1 Hz, 1H, H-6),
7.17−7.43 (m, 9H, H-8 + 8ArH), 7.89 (d, J4−3 = 5.0 Hz, 1H, H-4),
8.11 (d, J5−6 = 8.7 Hz, 1H, H-5), 8.14 (d, J3−4 = 5.0 Hz, 1H, H-3).
13C
NMR (100 MHz, DMSO-d6) δ (ppm): 23.2 (CH3), 47.7 (N-CH2),
70.2 (O-CH2), 95.4 (C-8), 110.4 (C-6), 112.9 (C-4), 114.9 (Cq),
123.1 (C-5), 125.8 (2C-ArH), 127.6 (C-ArH), 128.4 (C-ArH), 128.4
(C-ArH), 128.9 (C-ArH), 129.8 (Cq), 129.3 (C-ArH), 135.5 (Cq),
137.3 (Cq), 138.6 (C-3), 139.5 (Cq), 141.3 (Cq), 143.7 (Cq), 160.2
(Cq).
1-Methyl-2-benzyl-7-benzyloxy-9-benzyl-β-carbolin-2-ium
Bromide (5a). The title compound was synthesized according to the
general synthetic procedure B from 4a (0.07 g, 0.185 mmol) in the
presence of 1-bromomethylbenzene (0.316 g, 1.850 mmol). Yellow
powder; yield 36%; Rf = 0.30 (CH2Cl2/ethanol 85/15); mp 262 °C;
m/z [MH+] = 469.3. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 2.81
(s, 3H, CH3), 5.23 (s, 2H, O-CH2), 5.96 (s, 2H, N-CH2), 5.98 (s, 2H,
N-CH2), 6.94 (d, 2H, J = 7.1 Hz, ArH), 7.07 (d, 2H, J = 7.1 Hz, ArH),
7.18−7.45 (m, 12H, 11 ArH + H-6), 7.53 (s, 1H, H-8), 8.45 (d, 1H,
J5−6 = 8.7 Hz, H-5), 8.69 (d, 1H, J4−3 = 6.4 Hz, H-4), 8.82 (d, 1H, J3−4
= 6.2 Hz, H-3). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 16.5
(CH3), 48.8 (N-CH2), 60.3 (N-CH2), 70.6 (O-CH2), 95.5 (C-8),
113.3 (Cq), 114.2 (C-6), 115.2 (C-4), 125.4 (C-5), 125.9 (C-ArH),
127.1 (C-ArH), 128.0 (C-ArH), 128.6 (C-ArH), 128.8 (C-ArH), 129.0
(C-ArH), 129.5 (C-ArH), 129.6 (C-ArH), 133.9 (Cq), 135.2 (Cq),
135.8 (Cq), 136.7 (C-3), 136.7 (Cq), 138.1 (Cq), 140.1 (Cq), 148.5
(Cq), 163.3 (Cq).
1-Methyl-2-(4-ﬂuorobenzyl)-7-(3-ﬂuorobenzyl)oxy-9-(3-ﬂu-
orobenzyl)-β-carbolin-2-ium Bromide (5k). The title compound
was synthesized according to the general synthetic procedure B from
4b (0.125 g, 0.302 mmol) in the presence of 1-bromomethyl-4-
ﬂuorobenzene (0.570 g, 3.020 mmol).Yellow powder; yield 92%; Rf =
0.43 (CH2Cl2/ethanol 85/15); mp > 200 °C; m/z [MH
+] = 523.1. 1H
NMR (400 MHz, CD3OD) δ (ppm): 2.90 (s, 3H, CH3), 5.25 (s, 2H,
O-CH2), 5.92 (s, 2H, N-CH2), 5.95 (s, 2H, N-CH2), 6.74 (d, 1H, J =
9.6 Hz, ArH), 6.79 (d, 1H, J = 7.8 Hz, ArH), 6.97−7.03 (m, 2H,
2ArH), 7.10−7.35 (m, 10H, H-6 + H-8 + 8ArH), 8.37 (d, 1H, J5−6 =
9.4 Hz, H-5), 8.51 (d, 1H, J4−3 = 6.4 Hz, H-4), 8.64 (d, 1H, J3−4 = 6.6
Hz, H-3). 13C NMR (100 MHz, CD3OD) δ (ppm): 15.4 (CH3), 49.2
(N-CH2), 59.7 (N-CH2), 69.4 (O-CH2), 94.4 (C-8), 112.2 (d, J = 23.0
Hz, C-ArH), 113.4 (Cq), 113.8 (d, J = 23.0 Hz, C-ArH), 114.4 (C-4 +
C-6), 114.5 (d, J = 15.3 Hz, 2C-ArH), 115.9 (d, J = 22.0 Hz, 2C-ArH),
121.0 (d, J = 2.9 Hz, C-ArH), 122.9 (d, J = 1.9 Hz, C-ArH), 124.5 (C-
5), 128.8 (d, J = 8.6 Hz, 2C-ArH), 130.1 (d, J = 7.7 Hz, C-ArH), 130.1
(d, J = 2.9 Hz, Cq), 131.0 (d, J = 8.6 Hz, C-ArH), 134.6 (Cq), 135.8
(C-3), 136.13 (Cq), 139.2 (d, J = 7.7 Hz, Cq), 139.4 (Cq), 139.7 (d, J =
6.7 Hz, Cq), 148.5 (Cq), 162.8 (d, J = 247.3 Hz, Cq), 163.0 (d, J =
245.4 Hz, Cq), 163.4 (d, J = 246.3 Hz, Cq), 163.6 (Cq).
19F NMR (376
MHz, CD3OD) δ (ppm): −113.5 (s), −114.7 (s), −114.8 (s).
1-Methyl-2-benzyl-7-cyclohexylmethyloxy-9-cyclohexyl-
methyl-β-carbolin-2-ium Bromide (5o). The title compound was
synthesized according to the general synthetic procedure B from 4d
(0.125 g, 0.32 mmol) in the presence of 1-bromomethylbenzene
(0.547 g, 3.200 mmol). Yellow powder; yield 74%; Rf = 0.33 (CH2Cl2/
ethanol 85/15); > 200 °C; m/z [MH+] = 480.3. 1H NMR (400 MHz,
CD3OD) δ (ppm): 1.07−1.44 (m, 12H, (cyclohexyl)), 1.61−1.95 (m,
10H, (cyclohexyl)), 3.10 (s, 3H, CH3), 4.00 (d, 2H, J = 6.2 Hz, O-
CH2), 4.51 (d, 2H, J = 7.3 Hz, N-CH2), 6.00 (s, 2H, N-CH2), 7.08
(dd, 1H, J6−5 = 8.9 Hz, J6−8 = 2.1 Hz, H-6), 7.15−7.16 (m, 2H, ArH),
7.23 (d, 1H, J8−6 = 2,1 Hz, H-8), 7.35−7.44 (m, 3H, ArH), 8.25 (d,
1H, J5−6 = 8.9 Hz, H-5), 8.43 (d, 1H, J4−3 = 6.6 Hz, H-4), 8.60 (d, 1H,
J3−4 = 6.6 Hz, H-3).
13C NMR (100 MHz, CD3OD) δ (ppm): 15.6
(CH3), 25.4 (cyclohexyl), 25.6 (cyclohexyl), 25.8 (cyclohexyl), 26.2
(cyclohexyl), 29.5 (cyclohexyl), 30.2 (cyclohexyl)), 37.7 (cyclohexyl),
40.2 (cyclohexyl), 51.0 (N-CH2), 60.4 (N-CH2), 73.9 (O-CH2), 94,5
(C-8), 112.7 (Cq), 113.8 (C-4 + C-6), 123.9 (C-5), 126.3 (2C-ArH),
128.5 (C-ArH), 129.2 (2C-ArH), 134.4 (Cq), 134.5 (Cq), 135.4 (C-3),
135.5 (Cq), 139.2 (Cq), 149.1 (Cq), 164.1 (Cq).
Pharmacological Evaluation. Determination of the in Vitro
IC50. The colorimetric MTT assay was used, as described
previously.12a−d This test measures the number of metabolically
active, living cells that are able to transform the yellow product 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) into
the blue formazan dye via mitochondrial reduction. The amount of
formazan obtained at the end of the experiment, measured via
spectrophotometry, is directly proportional to the number of living
cells. Therefore, determination of the optical density enables a
quantitative measurement of the eﬀect of the investigated compounds
when compared with the control condition (untreated cells) and/or
cells treated with other reference compounds.
Five human cancer cell lines (two esophageal cancer and three
glioma cell lines) were obtained from either the European Collection
of Cell Cultures (ECACC; Salisbury, U.K.) or the American Type
Culture Collection (ATCC; Manassas, VA). The two esophageal
cancer cell lines were the OE21 squamous (ECACC code 96062201)
and the OE33 adenocarcinoma (ECACC code 9607808) cell lines.4c
The three glioma cell lines were the Hs683 oligodendroglioma cell
line12c,14,17,18 (ATCC code HTB-138) and the U37312c,14,17,18
(ECACC code 89081403) and T98G14,17 (ATCC code CRL-1690)
astroglioma cell lines.
To perform the assay, cells (5000−8000 cells/well depending on
the cell line examined) were grown in a 96-well, ﬂat-bottomed plate in
100 μL of medium. Each cell line was seeded in its appropriate culture
medium. The detailed experimental procedures are provided elsewhe-
re.12a−d Each experimental condition was run in six replicates.
Computer-Assisted Phase Contrast Microscopy (Quantita-
tive Videomicroscopy). The direct visualization of compound-
induced cytotoxic or cytostatic eﬀects was performed as described
elsewhere.13a−d
Analyses of DYRK1A Inhibition and Kinase Proﬁling. The
DYRK1A inhibitory activity of the various examined β-carbolines (see
Table 2) was performed at ProQinase GmbH (Freiburg, Germany), as
detailed previously.24a,b The anti-kinase activity of 5k was proﬁled on
358 kinases and 10 lipid kinases also at ProQinase. The materials and
methods used by ProQinase to perform the radiometric protein kinase
assay (33PanQinase activity assay) are fully detailed in the Supporting
Information of refs 24a and 24b. We originally provided ProQinase
with a stock solution of each compound in 100% DMSO, and the
aliquots were further diluted with water in 96-well microtiter plates
directly before use; 5 μL of a 2 × 105 M/10% DMSO solution was
transferred to the assay plates. The ﬁnal volume of the assay was 50
μL. The concentrations tested for each compound in order to
determine the IC50 value are detailed in the legend to Tables 2 and 3.
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Western Blott Analyses with the Eukaryotic Initiation Factor
2 (eIF2).We used a modiﬁed RIPA buﬀer to recover the largest part of
proteins from Hs683 and U373 glioma cells. This ice cold lysis buﬀer
is composed of 10 mM Tris (pH7.4), 100 mM NaCl, 1 mM EDTA, 1
mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 0.1% SDS,
0.5% sodium deoxycholate, 1% Triton-X 100, 10% glycerol, 1 mM
AEBSF (Perfabloc, Sigma), 60 μg/mL aprotinin, 10 μg/mL leupeptin,
and 1 μg/mL pepstatin.
The control and treated cells were lysed in this buﬀer and
centrifuged for 10 min at 13 000 rpm to eliminate the cellular debris.
The concentration of proteins has been determined by the BCA
protein assay (Thermoﬁsher, Erembodegem, Belgium); 35 μg of
proteins was loaded onto a denaturing polyacrylamide gel, and after
electrophoresis, the proteins were transferred in a PVDF membrane
(Thermoﬁsher). Equal loading and integrity of proteins was veriﬁed by
means of tubulin immunoblot analysis. The following primary
antibodies were used for Western blot analysis: anti-eIF2α (dilution
1/1000; Abcam; Cambridge, U.K.), anti-eIF2αS1 (phospho S51)
(dilution 1/1000; Abcam), and anti-α tubulin (dilution 1/2000;
Abcam). Western blots were developed using the Pierce SuperSignal
chemiluminescence system (Thermoﬁsher) and the Biorad XRS+
system (Biorad, Nazareth, Belgium).
Solubility Measurements. The solubility was evaluated according
to a method described previously.25 HPLC measurements were done
using method A.
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